Ipierian, Inc.

Imago Pharmaceuticals, Inc.

Nitrase Therapeutics, Inc.

Irene Griswold-Prenner

Nancy E Stagliano

Vu Cao Dang

Sami Hussain

Graham Parry

Tony SangYoung Byun

Karen Chen

Jessica Michelle Bright

The present invention features methods for identifying treatments for neurodegenerative diseases, e.g., Parkinson's disease. Described are purification methods for synuclein nitration enzyme and screening methods for identifying agents that inhibit synuclein nitration enzyme activity.

Identification of modulators of nitration and therapeutic uses thereof

The invention provides therapeutic antibodies and methods for treatment of diseases associated with diseases associated with aggregation of &#x3b1;-synuclein, e.g., in the brain of a subject. Such methods provide administration of therapeutic antibodies to elicit a beneficial immunogenic response against aggregation of &#x3b1;-synuclein. The methods are particularly useful for prophylactic and therapeutic treatment of diseases associated with the formation of Lewy bodies, e.g., Parkinson's disease.

Therapeutic antibodies for treatment of neurodegeneration

Isolated tau peptides, and compositions comprising the peptides are disclosed. Further provided are antibodies specific for an isolated tau peptide. Methods of using the isolated tau peptide in diagnostic and treatment including using a pharmaceutical composition comprising the isolated tau peptide for stimulating an immune response in an individual to a tau peptide, and methods of using antibodies in detection, diagnosis, and treatment of disorders including a tauopathy are further provided.

Tau peptides, anti-tau antibodies, and methods of use thereof

The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.

Growing community of inventors

Jackson, WY, United States of America

Irene Griswold-Prenner